Companies / Consumer Staples
CL
Colgate-Palmolive
Household Products
Household ProductsAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health61
Growth34
Profitability59
Cash generation86
Balance sheet39
Dilution control89
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)4.6%Revenue growth (FY)1.4%Revenue CAGR (3y)4.3%Gross margin60.1%Operating margin16.2%Net margin10.5%Free cash flow margin17.8%R&D / revenue1.8%Stock comp / revenue0.8%Net debt / operating cash flow1.83xCurrent ratio0.83Diluted share count change-1.5%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $17.4B | $18.0B | $19.5B | $20.1B | $20.4B |
| Gross profit | $10.4B | $10.2B | $11.3B | $12.2B | $12.3B |
| Operating income | $3.3B | $2.9B | $4.0B | $4.3B | $3.3B |
| Net income | $2.2B | $1.8B | $2.3B | $2.9B | $2.1B |
| Operating cash flow | $3.3B | $2.6B | $3.7B | $4.1B | $4.2B |
| Capital expenditure | $567M | $696M | $705M | $561M | $564M |
| Free cash flow | $2.8B | $1.9B | $3.0B | $3.5B | $3.6B |
| R&D | $307M | $320M | $343M | $355M | $366M |
| Stock-based comp | $135M | $125M | $122M | $135M | $155M |
| Buybacks | $1.3B | $1.3B | $1.1B | $1.7B | $1.2B |
| Cash | $832M | $775M | $966M | $1.1B | $1.3B |
| Total debt | $7.2B | $8.8B | $8.2B | $7.7B | $9.0B |
| Equity | $609M | $401M | $609M | $212M | $54M |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.